A Surprising Truth About Cancer Drugs: More Is Not Always Better
In this article
Dose Optimisation and De-escalation in Cancer Treatment: Reducing Toxicity Without Compromising Clinical Efficacy
Clarifying the terminology is essential to establish the discussion on a sound footing. The introduction of biological and targeted therapies into oncology has brought new concepts to pharmacokinetic and pharmacodynamic modelling.
CONCEPTS OF DOSE DE-ESCALATION AND OPTIMISATION
- Maximum Tolerated Dose (MTD): The highest clinical dose level that does not cause unacceptable dose-limiting toxicity in the patient.
- Optimal Biological Dose (OBD): The most appropriate dosage that maximises the drug's therapeutic effect on its target receptor or biological pathway while minimising toxicity.
- Dose De-escalation: An approach that reduces the dose or extends treatment intervals within a regimen of proven clinical efficacy to reduce side effects.
- Project Optimus (FDA Initiative): The FDA's current reform requiring OBD, rather than MTD, to be established through rational studies before oncology agents are licensed.
A Paradigm Shift: Is "More" Always "Better"?
In cytotoxic chemotherapy, antitumour efficacy generally increases linearly as the dose rises. However, with targeted drugs and monoclonal antibodies, increasing the dose after target receptor saturation does not increase efficacy; instead, it only escalates off-target toxicity. In modern oncology, the aim is to find "the safest, lowest effective dose that suppresses the tumour", rather than pushing the patient's tolerance to its limits.
Antibody-drug conjugates (ADCs) are potent agents combining the targeting power of monoclonal antibodies with a cytotoxic payload. Their narrow therapeutic indices, however, place them at the centre of dose-optimisation studies. In current oncology practice, dose optimisation in ADCs, toxicity management, the Project Optimus approach and long-term safety data are major discussion topics. Meanwhile, previously published data from DESTINY, CheckMate and various real-world analyses are being reassessed for the implications of dose modifications in clinical practice.
ADC DOSE MODIFICATIONS AND LEVELS OF EVIDENCE
- Management of Trastuzumab Deruxtecan (T-DXd): Reviewing pooled clinical data and current analyses from the DESTINY-Breast trials, dose modifications for grade 1-2 adverse events or suspected early-stage interstitial lung disease (ILD) have been evaluated (for example, moving from 5.4 mg/kg to 4.4 mg/kg). Available analyses suggest that dose modifications due to toxicity do not result in a substantial loss of efficacy.
- Sacituzumab Govitecan Data: Real-world and subgroup analyses have observed that dose reductions made according to protocol rules in patients developing severe neutropenia or diarrhoea do not dramatically impair overall antitumour response rates.
- Trends in Next-Generation Molecules: Examination of early-phase datasets is generating a strong clinical consensus that maintaining doses at the pharmacodynamically saturating OBD, rather than pushing them to the MTD limit, may significantly reduce the risk of peripheral neuropathy and haematological toxicity.
Clinical Warning: Toxicity Monitoring During ADC Treatment
Dose optimisation and flexibility do not mean relaxing toxicity monitoring. Particularly with drugs such as T-DXd, treatment should be suspended immediately when interstitial lung disease (ILD) or pneumonia is suspected, and management should begin according to guidelines. The primary aim of dose modifications is to safely extend the patient's time on treatment.
The pharmacokinetic properties of anti-PD-1 and anti-PD-L1 agents and their prolonged T-cell receptor occupancy have enabled the development of less frequent dosing schedules for maintenance therapy. This approach has also been approved by official authorities.
| Drug / Molecule | Standard Starting Dose | Approved / Optimised Extended Schedule | Clinical Evidence Base and Basis for Licensing |
|---|---|---|---|
| Pembrolizumab (Keytruda) | 200 mg every 3 weeks | 400 mg every 6 weeks | Based on FDA approval of pharmacokinetic modelling and clinical simulation. Real-world cohorts and maintenance periods have shown PFS and OS profiles consistent with the standard regimen. |
| Nivolumab (Opdivo) | 240 mg every 2 weeks | 480 mg every 4 weeks | Approved on the basis of CheckMate clinical simulations and exposure-response analyses. In maintenance cohorts, the extended interval is reported not to adversely affect the grade 3/4 immune-related adverse event (irAE) profile. |
| Durvalumab (Imfinzi) | 10 mg/kg every 2 weeks | 1500 mg Fixed Dose every 4 weeks | PACIFIC and the relevant registered maintenance cohorts have confirmed that the fixed-dose, less frequent regimen preserves biological saturation in pleural/pulmonary tissues. |
In clinical practice, dose reduction or less frequent treatment should be based on rational criteria. De-escalation may carry risks in cases with aggressive tumour biology or an inadequate response at initial assessments. In line with general clinical trends, patient selection can be summarised as follows:
✓ CANDIDATES WHO MAY BE SUITABLE FOR DE-ESCALATION
- Patients with a deep partial response (PR) or clinical complete response (CR) during the initial treatment cycles.
- Patients developing clinically intolerable chronic toxicity (for example persistent grade 2-3 peripheral neuropathy, palmar-plantar erythrodysesthesia).
- Patients with borderline organ reserves, frail patients or the geriatric population.
- Biologically slow-growing (indolent) tumour subtypes.
- Cases remaining stable over the long term during maintenance treatment.
✕ SITUATIONS IN WHICH MAINTAINING THE STANDARD DOSE IS RECOMMENDED
- Aggressive disease with a high tumour burden and a risk of rapid clinical progression.
- Neoadjuvant or adjuvant (early-stage) regimens administered with curative intent.
- Tumours with a suboptimal or borderline response at the first radiological assessment.
- Stable patients without major organ failure or additional comorbidities affecting drug blood levels and metabolism.
- Situations in which the targeted dose intensity is critical during the first treatment line.
Tyrosine kinase inhibitors (TKIs) are agents taken orally every day for long periods. Chronic low-grade toxicity in this group (such as persistent rash, diarrhoea or nail-bed changes) directly affects adherence and quality of life.
🔬 CLINICAL TRENDS IN TKI DOSE MODIFICATION
Management of Osimertinib: Pooled analyses of clinical trials have reported substantial preservation of antitumour efficacy and biological suppression of the target pathway in patients whose dose was reduced from 80 mg to 40 mg because of severe or intolerable grade 2+ adverse events (nail-bed toxicity, diarrhoea or rash). However, much of this evidence reflects selected, retrospective patient groups in clinical practice.
CDK4/6 Inhibitors (Breast Cancer): Subgroup analyses have reported that stepwise, guideline-directed dose reductions to manage neutropenia during palbociclib or ribociclib use (for example from 125 mg to 100 mg or 75 mg) do not weaken biological suppression of the cell cycle to a clinically significant extent.
The Cabozantinib Example (Renal Cell Carcinoma): In clinical trials, dose reductions (from 60 mg to 40 mg or 20 mg) have frequently been needed to manage adverse events. Data show that total treatment duration can be optimised in patients whose side effects are controlled through dose modification.
⚡ WHY DOES IT MATTER?
Modern oncology is questioning the "Maximum Tolerated Dose" (MTD) approach for biological agents. Guided by the FDA's Project Optimus guidance, the "Optimal Biological Dose" (OBD) of targeted therapies and ADCs is being investigated, aiming to maintain efficacy while protecting patients from toxicity.
✅ STRENGTHS OF THE EVIDENCE
Extended maintenance intervals for checkpoint inhibitors such as pembrolizumab and nivolumab are based on robust pharmacokinetic modelling and approval by official authorities. In ADC and TKI management, guideline-concordant dose reductions are known to contribute to clinical continuity by keeping patients on treatment.
⚠️ LIMITATIONS AND CONTRADICTIONS
A substantial proportion of the evidence for de-escalation and dose reduction with small-molecule targeted drugs comes from retrospective series or subgroup analyses rather than primary endpoints of prospective RCTs. Maintaining full dose intensity in curative (adjuvant) treatment remains the fundamental approach.
🩺 IMPLICATIONS FOR CLINICAL PRACTICE
When intolerable side effects occur in patients receiving targeted therapies or ADCs, clinicians can rationally implement guideline-permitted dose modifications without assuming that "efficacy will immediately be lost". The key is to balance treatment continuity with patient safety.
❓ QUESTIONS FOR THE FUTURE
Could dose optimisation become fully personalised in the future through patient-specific artificial intelligence modelling and dynamic biomarker monitoring? How will Project Optimus rules shape the preclinical phases of all molecules seeking new approval? Can even longer dosing intervals in maintenance immunotherapy be tested safely?
Dose optimisation and de-escalation strategies in cancer treatment represent a shift in oncology from the dogma of "the highest dose" to a model of "the most appropriate and safe dose". Clinical data and regulators' current approaches emphasise the importance of preserving quality of life and controlling toxicity in the success of modern agents. Approved extended immunotherapy schedules, rational dose modifications to manage ADC side effects, and TKI dose adjustments that improve tolerability are valuable clinical tools supporting adherence. For multidisciplinary oncology teams, the fundamental approach is to maintain the delicate balance between tumour control and patient safety in light of current scientific guidelines, without exceeding the patient's tolerance limits.
References
- FDA Oncology Center of Excellence. Project Optimus: Reforming the Dose Optimization and Selection Paradigm in Oncology Drug Development. U.S. Food and Drug Administration Guidance Documents, 2023-2026.
- Trastuzumab Deruxtecan Dose Modification Analysis. Pooled efficacy and safety analysis of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, 02, and 03. Journal of Clinical Oncology / JCO Precision Oncology (Clinical Data Registries).
- FDA Approved Labeling Documents. Keytruda (pembrolizumab) dosing regimens (400 mg Q6W) and Opdivo (nivolumab) dosing updates (480 mg Q4W). Drugs@FDA, Reference Records.
This article is a medical review for informational purposes; it does not provide individual treatment recommendations and does not replace clinical guidelines. Decisions to optimise or reduce doses or change treatment schedules in cancer therapy must be made only by the medical oncologist caring for the patient, according to disease stage, tumour biology, laboratory parameters and the severity of adverse events. Some data presented in this review are based on retrospective analyses or pharmacokinetic modelling, and the level of evidence for de-escalation is not the same for every molecule and indication. Changes to treatment protocols should be managed rationally, taking into account international guidelines (ASCO, ESMO, NCCN) and officially approved summaries of product characteristics.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.